Deal Watch: ASCO Includes Flurry Of Immuno-Oncology Combo Trial Partnerships
Executive Summary
Halozyme, Juno and bluebird bio were among the deal-makers during the annual cancer convention. Beyond that meeting, Vertex signed an R&D alliance with Parion Sciences that may expand its cystic fibrosis portfolio, while Sanofi bought another priority review voucher.